ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib is a second‐generation TKI with improved efficacy in terms of an earlier and deeper molecular response, lower rates of progression to accelerated or blast phase, fewer CML‐related deaths, and fewer treatment‐emergent BCR‐ABL1 mutations, when compared to imatinib 4, 5, 6.